Meeting
2015 Genitourinary Cancers Symposium
Outcomes of patients with late relapse metastatic renal cell carcinoma treated with targeted therapies: A single-institution experience.
Authors
Kamal Kishore Mandalapu
Ochsner Medical Center, New Orleans, LA
Kamal Kishore Mandalapu , Marc Ryan Matrana , Teja Poosarla
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Renal Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 33, 2015 (suppl 7; abstr 498)
DOI
10.1200/jco.2015.33.7_suppl.498
Abstract #
498
Poster Bd #
G26
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Cabozantinib (Cabo) beyond progression improves survival in advanced renal cell carcinoma patients: The CABEYOND study (Meet-Uro 21).
First Author: Giuseppe Procopio
Poster
2020 Genitourinary Cancers Symposium
Progression-free survival (PFS) and overall survival (OS) across ethnicities for patients with metastatic renal cell carcinoma (mRCC) receiving targeted therapies (TT) as first-line (1L) treatment.
First Author: Nicholas Salgia
Poster
2019 Genitourinary Cancers Symposium
Exploratory endpoints in a FARETES study of the efficacy of testosterone in metastatic renal cell carcinoma (mRCC) patients.
First Author: Ilya Tsimafeyeu
Poster
2017 Genitourinary Cancers Symposium
Fourth-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).
First Author: Igor Stukalin